[1] AKCHURIN OM. Chronic kidney disease and dietary measures to improve outcomes[J]. Pediatr Clin North Am, 2019, 66(1): 247. doi: 10.1016/j.pcl.2018.09.007
[2] PROVENZANO M, COPPOLINO G, FAGA T, et al. Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer[J]. Rev Cardiovasc Med, 2019, 20(4): 209. doi: 10.31083/j.rcm.2019.04.548
[3] QIAN Q. Salt, water and nephron: Mechanisms of action and link to hypertension and chronic kidney disease[J]. Nephrology (Carlton), 2018, 23(4): 44.
[4] 何然, 任洁, 印霞, 等. 维持性血液透析患者血压波动影响因素分析及其与慢性肾脏病-矿物质和骨异常的相关性研究[J]. 中国血液净化, 2021, 20(4): 254. doi: 10.3969/j.issn.1671-4091.2021.04.009
[5] 富丽, 刘胜阳, 张宝桐, 等. 慢性肾脏病矿物质和骨异常患者血清白细胞介素-18、分泌型Klotho和骨保护素的表达及意义[J]. 陕西医学杂志, 2019, 48(8): 1035. doi: 10.3969/j.issn.1000-7377.2019.08.021
[6] LIABEUF S, RYCKELYNCK JP, EL ESPER N, et al. Randomized clinical trial of sevelamer carbonate on serum klotho and fibroblast growth factor 23 in CKD[J]. Clin J Am Soc Nephrol, 2017, 12(12): 1930. doi: 10.2215/CJN.03030317
[7] 王传珍, 滕军燕, 赵振江, 等. 补肾活血方联合骨化三醇治疗绝经后骨质疏松症对骨密度及骨代谢指标的影响[J]. 辽宁中医杂志, 2020, 47(9): 60.
[8] 侯金花, 蒋琦, 刘志红. 2017 KDIGO临床实践指南更新: 慢性肾脏病矿物质与骨异常诊断、评估、预防和治疗[J]. 肾脏病与透析肾移植杂志, 2017, 26(5): 462. doi: 10.3969/j.issn.1006-298X.2017.05.015
[9] 余永武, 周加军, 张凌. 《中国慢性肾脏病矿物质和骨异常诊治指南》的解读与思考[J/CD]. 中华肾病研究电子杂志, 2020, 9(1): 17. doi: 10.3877/cma.j.issn.2095-3216.2020.01.004
[10] KAUPPILA LI, POLAK JF, CUPPLES LA, et al. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study[J]. Atherosclerosis, 1997, 132(2): 245. doi: 10.1016/S0021-9150(97)00106-8
[11] YERRAMILLI M, FARACE G, QUINN J, et al. Kidney disease and the nexus of chronic kidney disease and acute kidney injury: the role of novel biomarkers as early and accurate diagnostics[J]. Vet Clin North Am Small Anim Pract, 2016, 46(6): 961. doi: 10.1016/j.cvsm.2016.06.011
[12] VADEN SL, ELLIOTT J. Management of proteinuria in dogs and cats with chronic kidney disease[J]. Vet Clin North Am Small Anim Pract, 2016, 46(6): 1115. doi: 10.1016/j.cvsm.2016.06.009
[13] 陈德珠, 曾繁琨, 钟建, 等. 危重症脓毒症并发急性肾损伤进展至慢性肾脏病危险因素分析[J]. 天津医药, 2021, 49(2): 165.
[14] 丁照莹, 汤涛涛, 刘必成. 肾小管上皮细胞损伤在急性肾损伤向慢性肾脏病转变中的作用研究进展[J]. 中华医学杂志, 2021, 101(6): 442. doi: 10.3760/cma.j.cn112137-20200602-01750
[15] 谢晖, 沈瀚. 慢性肾脏病患者凝血功能变化及高凝状态影响因素分析[J]. 检验医学, 2021, 36(5): 500. doi: 10.3969/j.issn.1673-8640.2021.05.008
[16] 李润芝, 祝灵英. 血清骨硬化蛋白TRAP-5b在维持性血透慢性肾脏病-矿物质和骨异常诊断中的应用价值[J]. 浙江临床医学, 2020, 22(11): 1667.
[17] CASES A, EGOCHEAGA MI, TRANCHE S, et al. Anemia of chronic kidney disease: Protocol of study, management and referral to Nephrology[J]. Aten Primaria, 2018, 50(1): 60. doi: 10.1016/j.aprim.2017.09.007
[18] KETTELER M, SPRAGUE SM, COVIC AC, et al. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients[J]. Nephrol Dial Transplant, 2019, 34(7): 1163. doi: 10.1093/ndt/gfy127
[19] 李靖, 曹参, 吴勤研, 等. 碳酸司维拉姆对终末期肾脏病并发高磷血症病人磷钙及低密度脂蛋白胆固醇水平的影响[J]. 安徽医药, 2020, 24(3): 583.
[20] 贺丹, 陆志峰, 陆静娟. 碳酸司维拉姆对慢性肾衰竭合并高磷血症患者微炎症状况及预后的影响[J]. 河北医学, 2019, 25(11): 1850.
[21] PIKE JW, MEYER MB. The unsettled science of nonrenal calcitriol production and its clinical relevance[J]. J Clin Invest, 2020, 130(9): 4519.
[22] TSAI TH, LIN CJ, HANG CL, et al. Calcitriol attenuates doxorubicin-induced cardiac dysfunction and inhibits endothelial-to-mesenchymal transition in mice[J]. Cells, 2019, 8(8): 865.
[23] 魏昌林, 颜怀荣, 蔡小月, 等. 小剂量骨化三醇联合碳酸司维拉姆延缓维持性血液透析患者血管钙化的效果观察[J]. 临床误诊误治, 2020, 33(8): 45.